

INVITATION

JAK PARDY!



DEVELOPMENT COMMITTEE

Philip Baer, MDCM, FRCPC, FACR

Vice-President, Ontario Rheumatology Association
Past-Chair, Ontario Medical Association
Section on Rheumatology
Editor-in-Chief, Journal of the
Canadian Rheumatology Association
Toronto, Ontario

Michael Starr, MD, FRCPC

Assistant Professor of Medicine
McGill University
Division of Rheumatology, Montreal
University Health Center
Montreal, Quebec

JAKPARDY! is a new highly interactive learning program for allied health professionals treating rheumatoid arthritis (RA) developed by a pan-Canadian faculty meant to be tailored to the audience needs.

During this session, you will have the opportunity to connect with a renowned Canadian RA expert and discuss the current treatment landscape and supporting data to help better manage your patients.

PLEASE JOIN US IN THIS NEW ENGAGING AND INTERACTIVE PROGRAM GAME highlighting novel options in the management of RA.

LET'S PLAY!

LEARNING OBJECTIVES

After participating in JAKPARDY!, attendees will be able to:

- Describe important modern RA management considerations
- Evaluate the key phase 3 efficacy and safety data for available JAK inhibitors
- Discuss new data on JAK inhibitor therapy presented at EULAR 2020
- Have a great time while learning!

We hope you will be able to attend the following event:

MODERATOR:

DATE:

TIME:

FROM

TO

REGISTRATION LINK:

MEETING LINK:

Material intended exclusively for rheumatologists for training purpose. This is a personal and non-transferable invitation, any total or partial reproduction, alteration, sharing or improper use of this content without prior authorization from AbbVie Corporation is expressly prohibited. All rights reserved.
This material is protected by Copyrights and other intellectual property protection laws.

In compliance with the Innovative Medicines Canada Code of Ethical Practices, this invitation is extended to Healthcare Professionals only.

This program is made possible through financial support from AbbVie Canada